Age: 71.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site swelling, Lethargy, Pyrexia, Tinnitus, Urticaria
Clinical narrative: Light headed; unbalanced; fever 102; bloating; abdominal pain; loss of appetite; joint aches; lethargy; hives on arms; burning eyes; weak; whelp 3 inches in diameter at injection site; severe headache; ringing in ears; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 71-year-old female patient received BNT162b2 (BNT162B2), on 29Jun2022 at 10:45 as dose 3 (booster), single (Lot number: FJ4991) at the age of 71 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: PCN Sulfa drugs" (unspecified if ongoing); "Known allergies: PCN Sulfa drugs" (unspecified if ongoing); "Known allergies: triptans" (unspecified if ongoing); "GERD" (unspecified if ongoing); "Fribromyalgia (unspecified if ongoing); "osteopenia" (unspecified if ongoing); "osteoarthritis" (unspecified if ongoing); being evaluated for sleep disturbances" (unspecified if ongoing); "Covid-19" (unspecified if ongoing), notes: if covid prior vaccination Yes. Concomitant medication(s) included: ATELVIA; FIORICET; HYDROCODONE; MVI [VITAMINS NOS]; UBRELVY. Past drug history included: Tessalon perle, reaction(s): "Known allergies: tessalon perle"; Clindamycin, reaction(s): "Known allergies: clindimycin"; Demerol, reaction(s): "Known allergies: Demerol"; Statin for Known allergies:statin. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Lot Number: EL0142; Anatomical location: Arm Right; Administration Time: 09:00 AM), administration date: 29Jan2021, for COVID-19 Immunization; Bnt162b2 (DOSE 2, SINGLE; Lot Number: FJ4991; Anatomical location: Arm Left), for COVID-19 immunisation. The following information was reported: DIZZINESS (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "Light headed"; ABDOMINAL PAIN (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering"; ABDOMINAL DISTENSION (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "bloating"; EYE IRRITATION (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "burning eyes"; PYREXIA (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "fever 102"; URTICARIA (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "hives on arms"; ARTHRALGIA (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "joint aches"; LETHARGY (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering"; DECREASED APPETITE (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "loss of appetite"; TINNITUS (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "ringing in ears"; HEADACHE (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "severe headache"; BALANCE DISORDER (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "unbalanced"; ASTHENIA (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "weak"; INJECTION SITE SWELLING (non-serious) with onset 29Jun2022 at 12:00, outcome "recovering", described as "whelp 3 inches in diameter at injection site". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of dizziness, balance disorder, pyrexia, abdominal distension, abdominal pain, decreased appetite, arthralgia, lethargy, urticaria, eye irritation, asthenia, injection site swelling, headache, tinnitus.  Additional information: Other medication in 2 weeks. Other medical history.